Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

New study reveals mechanisms for UVA1 phototherapy in scleroderma

A new study shows that UVA1 phototherapy — a treatment strategy that uses specific wavelengths of ultraviolet light — may work to reduce scarring in scleroderma by activating the aryl hydrocarbon receptor (AhR). This finding implies that activating the AhR protein may offer therapeutic benefits in the chronic autoimmune…

Monocyte Profiles Can ID Distinct Groups in Systemic Scleroderma

Analyzing the global genetic activity of immune cells called monocytes can identify distinct groups among people with systemic scleroderma, a new study indicates. This type of analysis “may represent a viable mechanism for identifying patients and potentially their response to therapeutics,” its researchers wrote. The study, “…

Epstein-Barr Virus Reactivation Studied in SSc Patients

People with systemic sclerosis (SSc) show higher levels of certain antibodies against the Epstein-Barr virus, which is suggestive of dormant viral infections becoming reactivated in these patients, a new study shows. The study, “Detection of Epstein–Barr virus in systemic sclerosis patients: A molecular and serological based…

First Groups Enrolled in Trial of EHP-101 for Systemic Scleroderma

The first two groups of patients have been enrolled in a Phase 2a clinical trial that’s testing the cannabidiol-derived medication EHP-101 in people with systemic scleroderma (SSc), the therapy’s developer Emerald Health Pharmaceuticals (EHP) announced. Interim results are expected next year, according to EHP. Participants are currently…

Efzofitimod Scores FDA Fast Track Designation for SSc-ILD

The U.S. Food and Drug Administration (FDA) has granted the experimental therapy efzofitimod fast track status as a potential treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc). The designation is given to speed up the development and review of therapies designed to treat serious health conditions.

Long Non-coding RNAs in Pediatric Localized Scleroderma Profiled

Levels of a type of immune cell called T-cells are elevated in skin biopsies from children with localized scleroderma, a new study shows. The study showed that T-cells from pediatric localized scleroderma patients can promote scar-forming activity in skin cells when grown together in a laboratory culture. Researchers also…